Table II.
Background of the patients.
| S-groupa | L-groupb | |
|---|---|---|
| Male | 25 | 20 |
| Female | 16 | 8 |
| Mean age (years) | 71.1±7.4 | 71.0±9.0 |
| Positive for anti-HCV | 38 | 21 |
| Positive for HBsAg | 0 | 5 |
| Positive for both anti-HCVAb and HBsAg | 3 | 0 |
| Negative for both anti-HCVAb and HBsAg | 0 | 2 |
| Past history of HCC | ||
| Positive | 16 | 11 |
| Negative | 25 | 17 |
| No. of tumors | 49 | 30 |
| Tumor size (cm) | 1.42±0.39 | 3.03±1.10 |
| AST (IU/l) | 73.6±100.9 | 66.8±42.5 |
| ALT (IU/l) | 52.3±55.9 | 51.4±31.3 |
| T-bil (mg/dl) | 0.92±0.47 | 1.07±0.80 |
| TP (g/dl) | 7.3±0.8 | 7.1±0.7 |
| ALB (g/dl) | 3.7±0.6 | 3.7±0.6 |
| PLT (*104/μl) | 11.8±6.10 | 13.3±8.9 |
| PT (%) | 72.1±10.4 | 74.5±14.4 |
| AFP | 89.4±300.0 | 142.1±360.8 |
a
HCC diameter ≤2 cm.
b
HCC diameter >2 cm.
anti-HCV Ab, anti-hepatitis C virus antibody; HBsAg, hepatitis B virus surface antigen; HCC, hepatocellular carcinoma; AST, aspartate aminotransferase; ALT, alanine aminotransferase; T-bil, total bilirubin; TP, total protein; ALB, albumin; PLT, platelets; PT, prothrombin time and AFP, α fetoprotein.